Society for Immunotherapy of Cancer (SITC) 2021 - Biognosys
Contact us Helpdesk

Society for Immunotherapy of Cancer (SITC) 2021

 

At this year’s SITC 21, we will host a Launch Exhibition for our next-generation Plasma Biomarker Discovery solution. The launch also features a Launch Webinar on November 9th.

 

Biognosys is proud to present a scientific poster highlighting the results from our ultra-deep, unbiased plasma proteomics workflow in a pan-cancer clinical trial. Additionally, Parker Institute for Cancer Immunotherapy (PICI) will share the results of our proteomic analysis in the PRINCE trial in metastatic pancreatic cancer.

 

We are excited to meet you in person at booth #609.

Poster Presentations

Unbiased proteomic profiling leads to the discovery of a novel non-invasive blood-based protein panel with significant positive predictive value in pancreatic and colorectal cancers

Authors: Kristina Beeler, Dr.; Roland Bruderer, PhD; Marco Tognetti, PhD; Kamil Sklodowski, PhD; Sebastian Mueller, PhD; Dominique Kamber; Lukas Reiter, PhD

Poster Number: 90

Poster Presentation

Multiomic biomarker signatures identify subsets of patients who may benefit from either nivolumab or sotigalimab in combination with chemotherapy in metastatic pancreatic cancer.

Authors: Deena M. Maurer, PhD; Jia Xin Yu, PhD; Kamil Sklodowski, PhD; Marco Tognetti, PhD; Lukas Reiter, PhD; Roland Bruderer, PhD; Jakob Vowinckel, PhD; Shannon M. Pfeiffer, MS; Mark H. O’Hara, MD; Eileen M. O’Reilly, MD; Robert A. Wolff, MD; Zev A. Wainberg, MD; Andrew H. Ko, MD; Osama Rahm, MD; George A. Fisher, MD; Jaclyn P. Lyman, MS; Christopher R. Cabanski, PhD; Pier Federico Gherardini, PhD; Jill O’Donnell-Tormey, PhD; Theresa M. LaVallee, PhD; Robert H. Vonderheide, MD, PhD; Lacey J. Kitch, PhD

Poster Number: 343

Poster Presentation